Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
Clinical trial NCT03814746 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03814746
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-26
- Primary completion
- 2022-08-31
- Enrollment
- 254
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.